Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO IMPORTANT BUSINESS COOPERATION AGREEMENTS AND APPROVAL OF BEIJING KEY LABORATORY FOR INNOVATION AND TRANSLATION OF PRECISION AND INTELLIGENT DIAGNOSIS AND TREATMENT FOR MENTAL DISORDERS

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purposes of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the Company has recently entered into important business cooperation agreements (the "**Business Cooperation Agreement(s)**") with Peking University Sixth Hospital (北京大學第六醫院) and Shandong Mental Health Center (山東省精神衛生中心) (the "**Cooperator(s)**"), respectively, for the research and development (R&D) and commercialization of digital therapeutics products in mental health. In addition, the "Beijing Key Laboratory for Innovation and Translation of Precision and Intelligent Diagnosis and Treatment for Mental Disorders (精神疾病精準智能診療創新轉化北京市重點實驗室)" (the "**Laboratory**") jointly declared by the Company, Peking University Sixth Hospital and National Engineering Research Center for Software Engineering of Peking University (北京大學軟件工程國家工程研究中心) has obtained official approval for establishment.

I. ENTERING INTO BUSINESS COOPERATION AGREEMENT WITH PEKING UNIVERSITY SIXTH HOSPITAL

1. Scopes of Joint R&D

Research scopes include, among others, R&D and clinical application of digital therapeutics, research on the effectiveness of cognitive digital therapeutics for attention deficit hyperactivity disorder (ADHD) and precision and intelligent diagnosis and treatment system for depression. The research will cover the development of digital therapeutics products for emotional behavior problems throughout the lifespan and clinical verification, including the effectiveness and compliance study of cognitive digital therapeutics in enhancing the learning abilities among children with attention deficit hyperactivity disorder, the R&D and effectiveness study of "home-school-medical" digital collaborative intervention therapy for emotional disorders in children and adolescents, the R&D and clinical validation of cognitive digital therapeutics products for adults with ADHD, the R&D and clinical research of ADHD coaching courses and digital products, the development of multi-modal diagnosis technology for depression, the development of a hierarchical intervention system based on depression severity, the establishment of a precise, accessible and safe stepped-care intervention platform for depression and the provision of digital therapeutics solutions. It also includes the further optimization of electronic cognitive assessment and intervention tasks and personalized recommendation algorithms to improve targeted cognitive digital therapeutics.

2. Scopes of Commercial Cooperation

Collaborations on digital technology services for cognitive impairment diagnosis and treatment, and joint establishment of diagnosis and treatment services and health management systems for cognitive impairment covering the elderly, children and adults, will be conducted.

II. ENTERING INTO BUSINESS COOPERATION AGREEMENT WITH SHANDONG MENTAL HEALTH CENTER

1. Scopes of Joint R&D

Scopes of joint R&D include developing a cognitive screening and intervention system for mental disorders, a virtual human-guided containment capacity training method and system, and conducting research on mentalization-based treatment methods and systems utilizing virtual humans and large language models based on such systems.

2. Scopes of Commercial Cooperation

Collaborations on digital technology services for cognitive impairment diagnosis and treatment, and joint establishment of diagnosis and treatment services and health management systems for cognitive impairment covering the elderly, children and adults, will be conducted.

III. APPROVAL OF THE "BEIJING KEY LABORATORY FOR INNOVATION AND TRANSLATION OF PRECISION AND INTELLIGENT DIAGNOSIS AND TREATMENT FOR MENTAL DISORDERS"

The Company, as a core co-construction unit, has officially obtained approval for the establishment of the "Beijing Key Laboratory for Innovation and Translation of Precision and Intelligent Diagnosis and Treatment for Mental Disorders", jointly established with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering of Peking University. The Laboratory will focus on collaborative R&D aimed at innovation and transformation guided by the clinical needs of mental and psychological disorders and the Laboratory will bring together multidisciplinary strengths in clinical medicine, basic research, technological development, and hardware innovation. It will establish a collaborative R&D model characterized by "clinical demand-driven approaches, foundational research support, integrated software-hardware development, and end-to-end translation (臨床驅動、基礎支撐、軟硬結合、貫通轉化)". The Company will primarily be responsible for core technology R&D, productization and user experience optimization in the field of innovation and translation of precision and intelligent diagnosis and treatment for mental disorders. This will further solidify the Group's technological leadership in the domain of digital therapeutics for mental health.

IV. REGARDING THE COOPERATORS

1. Peking University Sixth Hospital

Peking University Sixth Hospital (Peking University Institute of Mental Health (北京大學精神衛生研究所) and Peking University School of Mental Health (北京大學精神衛生學院)) was founded in 1942. It is a tertiary Grade A specialized psychiatric hospital that integrates clinical medical services, talent training, scientific research, and public health services. It is a "dual-center (雙中心)" institution within China's mental health field, housing both the National Clinical Research Center for Mental Disorders (國家精神心理疾病臨床醫學研究中心) and the National Center for Mental Disorders (國家精神疾病醫學中心). Peking University Sixth Hospital maintains a leading position domestically and enjoys international recognition in clinical diagnosis and treatment, scientific research and innovation, talent cultivation and public health services.

2. Shandong Mental Health Center

Shandong Mental Health Center (Shandong University Affiliated Mental Health Center (山東大學附屬精神衛生中心)), established in 1954, is a grade A tertiary specialized psychiatric hospital integrating medical services, teaching, scientific research, prevention and treatment. Shandong Mental Health Center boasts outstanding disciplinary strength, and implements cutting-edge diagnostic and therapeutic technologies. As a regional pioneer, it operates 10 major research platforms and collaborates with over 100 institutions within and outside Shandong Province.

V. REASONS AND BENEFITS FOR THE COOPERATIONS

To date, the Company has established close commercial cooperation with Beijing Anding Hospital, Capital Medical University (首都醫科大學附屬北京安定醫院) (a grade A tertiary specialized psychiatric hospital serving as the National Medical Center for Mental Disorders, National Clinical Research Center for Psychiatric and Psychological Disorders) to jointly promote the clinical application of digital therapeutics products for mental health. The cooperations with Peking University Sixth Hospital and Shandong Mental Health Center further expands the Company's coverage in China's core specialized psychiatric hospitals, establishing a multi-tiered commercial implementation network spanning national flagship centers, regional hubs, and key specialty hospitals.

The Board is of view that the implementation of the aforementioned Business Cooperation Agreements and the approval of the Laboratory will further consolidate the Company's first-mover advantage in the field of digital therapeutics for mental health, accelerate the product R&D and commercialization, and enhance the Company's core position in the collaborative innovation system integrating "industries, universities, research institutes and medical practitioners", and lay a solid foundation for the long-term business development of the Company. The Company will continue to promote cooperation with other top medical institutions and build a nationwide digital mental health service system integrating industries, universities, research institutes and medical practitioners.

VI. IMPLICATIONS UNDER THE LISTING RULES

To the best of the knowledge and belief of the Company, the Cooperators and their respective shareholders are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The transactions contemplated under this cooperation do not constitute any connected transaction of the Company under Chapter 14A of the Listing Rules, nor does it constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules.

As the research projects under the Business Cooperation Agreements are still in the research stage and the Laboratory is still in the preparatory stage, shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, January 6, 2026

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.